Hong Kong Stock Movers: INNOGEN-B Surges Over 18% in Early Trading After Two Suzhou Pegloticase Alpha Injection Contract Sites Achieve PIC/S GMP Certification

Stock News08-04

INNOGEN-B (02591) saw its shares climb more than 18% in early trading, though they later pared gains to trade up 10.23% at HK$7.815, with turnover reaching HK$23.282 million.

Driving the move, INNOGEN announced on August 3 that on July 27, 2026, two of its contract manufacturing sites in China passed a compliance inspection by Brazil's National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards, and have received the relevant GMP certificates.

The company stated that obtaining the PIC/S GMP certificates confirms that the drug substance and finished product manufacturing and quality management systems at the contract sites meet PIC/S GMP standards. This achievement is expected to further expand the commercial production capacity for INNOGEN's Suzhou Pegloticase Alpha injection and accelerate the drug's registration and commercialization process within PIC/S member countries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171803840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171803840","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movers: INNOGEN-B Surges Over 18% in Early Trading After Two Suzhou Pegloticase Alpha Injection Contract Sites Achieve PIC/S GMP Certification","media":"Stock News","content":"<p><b>INNOGEN-B</b> (<b>02591</b>) saw its shares climb more than 18% in early trading, though they later pared gains to trade up 10.23% at HK$7.815, with turnover reaching HK$23.282 million.<br><br>Driving the move, INNOGEN announced on August 3 that on July 27, 2026, two of its contract manufacturing sites in China passed a compliance inspection by Brazil's National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards, and have received the relevant GMP certificates.<br><br>The company stated that obtaining the PIC/S GMP certificates confirms that the drug substance and finished product manufacturing and quality management systems at the contract sites meet PIC/S GMP standards. This achievement is expected to further expand the commercial production capacity for INNOGEN's Suzhou Pegloticase Alpha injection and accelerate the drug's registration and commercialization process within PIC/S member countries.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movers: INNOGEN-B Surges Over 18% in Early Trading After Two Suzhou Pegloticase Alpha Injection Contract Sites Achieve PIC/S GMP Certification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movers: INNOGEN-B Surges Over 18% in Early Trading After Two Suzhou Pegloticase Alpha Injection Contract Sites Achieve PIC/S GMP Certification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-04 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>INNOGEN-B</b> (<b>02591</b>) saw its shares climb more than 18% in early trading, though they later pared gains to trade up 10.23% at HK$7.815, with turnover reaching HK$23.282 million.<br><br>Driving the move, INNOGEN announced on August 3 that on July 27, 2026, two of its contract manufacturing sites in China passed a compliance inspection by Brazil's National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards, and have received the relevant GMP certificates.<br><br>The company stated that obtaining the PIC/S GMP certificates confirms that the drug substance and finished product manufacturing and quality management systems at the contract sites meet PIC/S GMP standards. This achievement is expected to further expand the commercial production capacity for INNOGEN's Suzhou Pegloticase Alpha injection and accelerate the drug's registration and commercialization process within PIC/S member countries.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"","article_id":"1171803840","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171803840","pubTimestamp":1785807856,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) saw its shares climb more than 18% in early trading, though they later pared gains to trade up 10.23% at HK$7.815, with turnover reaching HK$23.282 million.Driving the move, INNOGEN...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股","02591":"银诺医药-B","BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard"},"translate_title":"港股推动者：苏州聚乙二醇肽酶α注射液两个合同点获得PIC/S GMP认证后，INNOGEN-B早盘飙升逾18%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1,"02591":1,"VXUS":1},"content_text":"INNOGEN-B (02591) saw its shares climb more than 18% in early trading, though they later pared gains to trade up 10.23% at HK$7.815, with turnover reaching HK$23.282 million.Driving the move, INNOGEN announced on August 3 that on July 27, 2026, two of its contract manufacturing sites in China passed a compliance inspection by Brazil's National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards, and have received the relevant GMP certificates.The company stated that obtaining the PIC/S GMP certificates confirms that the drug substance and finished product manufacturing and quality management systems at the contract sites meet PIC/S GMP standards. This achievement is expected to further expand the commercial production capacity for INNOGEN's Suzhou Pegloticase Alpha injection and accelerate the drug's registration and commercialization process within PIC/S member countries.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171803840","isCrawlerRequest":true}